Applying to Clinical Trial: A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Contact this trialFirst, we need to learn more about you.

Alkylating agents

Cyclophosphamide +2 More for Breast Cancer

Recruiting2 awardsPhase 3

Henderson, Nevada

This trial is testing if adding the drug bevacizumab to standard chemotherapy can help prevent HER2-negative breast cancer from returning and improve survival rates. Researchers also want to learn about any side effects from the combination of drugs.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and .

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our